These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37639050)

  • 21. The constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617.
    Gnanasambandan K; Magis A; Sayeski PP
    Biochemistry; 2010 Nov; 49(46):9972-84. PubMed ID: 20958061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
    Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
    Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K; Shimoda K
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center.
    Davila-Gonzalez D; Barrios-Ruiz A; Fountain E; Cheng L; Masarova L; Verstovsek S; Rojas-Hernandez CM
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):224-229. PubMed ID: 33349602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.
    Karkucak M; Yakut T; Ozkocaman V; Ozkalemkas F; Ali R; Bayram M; Gorukmez O; Ocakoglu G
    Mol Biol Rep; 2012 Sep; 39(9):8663-7. PubMed ID: 22722988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JAK2 V617F mutation testing in polycythemia vera: use and impact in an academic practice.
    Means RT
    Am J Med Sci; 2008 Oct; 336(4):327-9. PubMed ID: 18854675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis.
    Ohyashiki JH; Hisatomi H; Shimizu S; Sugaya M; Ohyashiki K
    Jpn J Clin Oncol; 2009 Aug; 39(8):509-13. PubMed ID: 19491085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.
    Leroy E; Balligand T; Pecquet C; Mouton C; Colau D; Shiau AK; Dusa A; Constantinescu SN
    J Allergy Clin Immunol; 2019 Jul; 144(1):224-235. PubMed ID: 30707971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
    Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
    Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low
    Makarik TV; Abdullaev AO; Nikulina EE; Treglazova SA; Stepanova EE; Subortseva IN; Kovrigina AM; Melikyan AL; Kulikov SM; Sudarikov AB
    Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33921387
    [No Abstract]   [Full Text] [Related]  

  • 32. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2
    Pang Y; Gupta G; Yang C; Wang H; Huynh TT; Abdullaev Z; Pack SD; Percy MJ; Lappin TRJ; Zhuang Z; Pacak K
    BMC Cancer; 2018 Mar; 18(1):286. PubMed ID: 29534684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
    Nagao T; Kurosu T; Umezawa Y; Nogami A; Oshikawa G; Tohda S; Yamamoto M; Miura O
    PLoS One; 2014; 9(1):e84746. PubMed ID: 24404189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations.
    Li S; Kralovics R; De Libero G; Theocharides A; Gisslinger H; Skoda RC
    Blood; 2008 Apr; 111(7):3863-6. PubMed ID: 18195094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polycythemia vera: the current status of preclinical models and therapeutic targets.
    Bartalucci N; Guglielmelli P; Vannucchi AM
    Expert Opin Ther Targets; 2020 Jul; 24(7):615-628. PubMed ID: 32366208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
    Oh ST; Gotlib J
    Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
    Benati M; Montagnana M; Danese E; De Matteis G; Veneri D; Paviati E; Guidi GC
    Clin Chem Lab Med; 2015 Jun; 53(7):1005-11. PubMed ID: 25527813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.
    Rapado I; Albizua E; Ayala R; Hernández JA; Garcia-Alonso L; Grande S; Gallardo M; Gilsanz F; Martinez-Lopez J
    Ann Hematol; 2008 Sep; 87(9):741-9. PubMed ID: 18575865
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H
    Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.